Our Company
- Premark Pharma is a privately-owned company, established in Switzerland in April 2018
- The lead investor is a consortium of US-based ophthalmologists
- The team includes experts in ophthalmic clinical practice, drug development and strategic marketing
Our Target
- Blepharitis is a common, chronic inflammatory eye disease for which there is currently no approved treatment
- Premark Pharma’s primary business objective is to achieve marketing approvals in EU and US for pimecrolimus formulations to treat blepharitis, dry eye and ocular surface inflammation
Our Lead Assets
- Premark’s lead assets are novel ophthalmic formulations of pimecrolimus, a well characterised and clinically proven topical anti-inflammatory compound
- PMP2207 is an ointment specifically formulated for the treatment of blepharitis. Phase 3 studies will commence shortly
- PMP1606 is a liquid suspension for the treatment of dry eye and inflammatory diseases of the ocular surface. A Phase 3 programme is currently being planned